Dr. Bernie Eigl, MD, FRCPC
Dr. Bernie Eigl is a distinguished medical oncologist specializing in genitourinary cancers, particularly prostate and bladder cancers. He graduated from McMaster University and completed his oncology training and genitourinary fellowship at the BC Cancer Agency. Currently, Dr. Eigl holds significant leadership positions at BC Cancer and the University of British Columbia. He serves as the Provincial Director of Systemic Therapy Clinical Trials, Founding Director of the Provincial Clinical Trials Office, and Deputy Head of the Department of Clinical Research at BC Cancer. In these roles, Dr. Eigl focuses on strengthening and expanding clinical trial capabilities across all six BC Cancer centres. His leadership ensures enhanced access to cutting-edge treatments for cancer patients throughout British Columbia.
Dr. Eigl's research interests centre on advancing genitourinary oncology through innovative clinical trials and biomarker research, with a specific emphasis on bladder cancer. He leads multiple clinical trials investigating novel therapies, including antisense oligonucleotides and oncolytic viruses. Dr. Eigl is actively involved in national and international oncology research groups, contributing significantly to the field's understanding and treatment of genitourinary cancers. His overarching goal is to improve patient outcomes by developing and implementing personalized treatment approaches based on biomarker research findings. Through his leadership and research efforts, Dr. Eigl continues to shape the landscape of genitourinary oncology, aiming to pioneer new standards of care and enhance the quality of life for cancer patients worldwide.
Recent Publications
Bladder Preservation in Muscle Invasive Bladder Cancer (MIBC): A Population Based Analysis (G. Ozgun, B. Eigl and S. Parimi., 2024, J. Clin. Oncol.)
Practice Patterns of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Canadian Practice (G.T. Gotto et al., 2024, J. Clin. Oncol.)
Abstract A007: Circulating Tumor DNA and Tissue Staining Analyses Reveal Heterogeneous ERBB2/HER2 Status in Urothelial Cancer (G. Vandekerkhove et al., 2024, Clin. Cancer Res.)
Abstract A004: Clinical Test Design Affects Tumor Tissue and ctDNA FGFR Gene Status in Metastatic Urothelial Cancer: A Prospective Study (D.C. Müller et al., 2024, Clin. Cancer Res.)